| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PY30 from our risk checks.
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 16.40 |
| 52 Week High | CHF 18.60 |
| 52 Week Low | CHF 15.30 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 5.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| PY30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | 3.7% | 1.1% |
| 1Y | n/a | -7.6% | 18.9% |
Return vs Industry: Insufficient data to determine how PY30 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PY30 performed against the German Market.
Price Volatility
| PY30 volatility | |
|---|---|
| PY30 Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PY30 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine PY30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,545 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| PY30 fundamental statistics | |
|---|---|
| Market cap | €19.95b |
| Earnings (TTM) | -€13.07m |
| Revenue (TTM) | €3.97b |
5.0x
P/S Ratio-1,526x
P/E RatioIs PY30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PY30 income statement (TTM) | |
|---|---|
| Revenue | US$4.32b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$3.00b |
| Other Expenses | US$3.02b |
| Earnings | -US$14.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 69.54% |
| Net Profit Margin | -0.33% |
| Debt/Equity Ratio | 37.1% |
How did PY30 perform over the long term?
See historical performance and comparison